title: Successful treatment using low-dose dasatinib for chronic myelogenous leukemia in a patient with megakaryoblastic transformation concomitant with myelofibrosis and an extramedullary tumor.
authors.forename: Masaki
authors.initials: M
authors.lastname: Yamaguchi
authors.forename: Saori
authors.initials: S
authors.lastname: Munemoto
authors.forename: Atsuo
authors.initials: A
authors.lastname: Kasada
authors.forename: Ryoichi
authors.initials: R
authors.lastname: Murata
authors.forename: Mikio
authors.initials: M
authors.lastname: Ueda
mesh_terms: D000368:Aged; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D002471:Cell Transformation, Neoplastic; D000069439:Dasatinib; D004305:Dose-Response Relationship, Drug; D006801:Humans; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000150:complications / Q000188:drug therapy* / Q000473:pathology; D008297:Male; D055728:Primary Myelofibrosis / Q000150:complications*; D011743:Pyrimidines / Q000627:therapeutic use*; D013844:Thiazoles / Q000627:therapeutic use*
chemical_list: D000970:Antineoplastic Agents; D011743:Pyrimidines; D013844:Thiazoles; D000069439:Dasatinib